Contents

Highlights of This Issue 4683

SPECIAL FEATURES

CCR Translations

4685 Location, Location, Location-Makes All the Difference for Hypoxia in Lung Tumors
Amit Maity and Constantinos Koumenis
See article p. 4843

CCR New Strategies

4688 New Strategies in Hepatocellular Carcinoma: Genomic Prognostic Markers
Augusto Villanueva, Yujin Hoshida, Sara Toffanin, Anja Lachenmayer, Clara Alsinet, Radoslav Savic, Helena Cornella, and Josep M. Llovet

Molecular Pathways

4695 Wnt/β-Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy
Luca Gattinoni, Yun Ji, and Nicholas P. Restifo

Review

4702 Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer
Carey K. Anders, Eric P. Winer, James M. Ford, Rebecca Dent, Daniel P. Silver, George W. Sledge, and Lisa A. Carey

HUMAN CANCER BIOLOGY

4711 Involvement of Human Herpesvirus-6 Variant B in Classic Hodgkin’s Lymphoma via DR7 Oncoprotein
Aurélie Lacroix, Sophie Collot-Teixeira, Laurent Mardivirin, Arnaud Jaccard, Barbara Petit, Christophe Piguet, Franck Sturz, Pierre-Marie Preux, Dominique Bordessoule, and Sylvie Ranger-Rogez

4722 Comprehensive Analysis of the MYB-NFIB Gene Fusion in Salivary Adenoid Cystic Carcinoma: Incidence, Variability, and Clinicopathologic Significance
Yoshitsugu Mitani, Jie Li, Pulivarthi H. Rao, Yi-jue Zhao, Diana Bell, Scott M. Lippman, Randy S. Weber, Carlos Caulin, and Adel K. El-Naggar

4732 Hypoxia Inducible Factor 1α and Hypoxia Inducible Factor 2α Play Distinct and Functionally Overlapping Roles in Oral Squamous Cell Carcinoma
Gui-quan Zhu, Ya-ling Tang, Ling Li, Min Zheng, Jian Jiang, Xiao-yu Li, Si-xiu Chen, and Xin-hua Liang

CANCER THERAPY: PRECLINICAL

4742 Role of CAAT/Enhancer Binding Protein Homologous Protein in Panobinostat-Mediated Potentiation of Bortezomib-Induced Lethal Endoplasmic Reticulum Stress in Mantle Cell Lymphoma Cells
Rekha Rao, Srikrutha Nalluri, Warren Fiskus, Andrew Savoie, Kathleen M. Buckley, Kyungsoo Ha, Ramesh Balasu, Atul Joshi, Veena Coothankandaswamy, Jianguo Tao, Eduardo Sotomayor, Peter Atadja, and Kapil N. Bhalla

4755 Mitochondrial-Mediated Apoptosis in Lymphoma Cells by the Diterpenoid Lactone Andrographolide, the Active Component of Andrographis paniculata
Shuo Yang, Andrew M. Evens, Sheila Prachand, Amareshwar T.K. Singh, Savita Bhalla, Kevin David, and Leo I. Gordon
Phase I Pharmacokinetic and Pharmacodynamic Evaluation of Combined Valproic Acid/Doxorubicin Treatment in Dogs with Spontaneous Cancer

IMAGING, DIAGNOSIS, PROGNOSIS

Hypoxia in Models of Lung Cancer: Implications for Targeted Therapeutics
Edward E. Graves, Marta Vilalta, Ivana K. Cecic, Janine T. Erler, Phuoc T. Tran, Dean Felsher, Leanne Sayles, Alejandro Sweet-Cordero, Quy nh-Thu Le, and Amato J. Giaccia
See commentary p. 4685

Biomarkers Predicting Outcome in Patients with Advanced Renal Cell Carcinoma: Results from Sorafenib Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial
Carol Peña, Chetan Lathia, Minghua Shan, Bernard Escudier, and Ronald M. Bukowski

Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types
Matthew D. Wilkerson, Xiaoying Yin, Katherine A. Hoadley, Yufeng Liu, Michele C. Hayward, Christopher R. Cabanski, Kenneth Muldrew, C. Ryan Miller, Scott H. Randell, Mark A. Socinski, Alden M. Parsons, William K. Funkhouser, Philip S. Bernard, Charles M. Perou, and D. Neil Hayes

CANCER THERAPY: CLINICAL

Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors
José Baselga, Andrés Cervantes, Erika Martinelli, Isabel Chirivella, Klaas Hoekman, Herbert I. Hurwitz, Duncan I. Jodrell, Paul Hamberg, Esther Casado, Paul Elvin, Alan Swaisland, Renee Iacona, and Josep Tabernero
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4892</td>
<td>Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy</td>
<td>Jenny J. Hong, Steven A. Rosenberg, Mark E. Dudley, James C. Yang, Donald E. White, John A. Butman, and Richard M. Sherry</td>
</tr>
<tr>
<td>4899</td>
<td>Inhibition of Carboplatin-Induced DNA Interstrand Cross-link Repair by Gemcitabine in Patients Receiving these Drugs for Platinum-Resistant Ovarian Cancer</td>
<td>Jonathan A. Ledermann, Hani Gabra, Gordon C. Jayson, Victoria J. Spanswick, Gordon J.S. Rustin, Mark Jitlal, Lindsay E. James, and John A. Hartley</td>
</tr>
</tbody>
</table>

**ABOUT THE COVER**

Preclinical toxicology analysis of Gamitrinibs. Animals carrying prostate cancer xenografts and treated systemically with vehicle or Gamitrinib-TPP (G-TPP) were sacrificed at the end of treatment and organs were collected and analyzed histologically. A representative image of spleen from the vehicle group is shown. For further details, please see the article by Kang and colleagues on page 4779 of this issue.